Background: Smart drug use is increasing but we have little insight into their use. We hypothesized that use is predicted by attitudes and various factors including incremental morality and entity intelligence beliefs would be associated with positive attitudes, whilst perception of unfairness would be associated with negative attitudes.
Methods: UK undergraduates completed an online survey to establish attitudes towards smart drugs, previous use and likely future use as well as measures of several factors hypothesized to predict attitudes.
Results: Attitudes were found to predict previous and likely future use. Attitudes were more positive in those who believed that smart drugs were harmless and those who felt they knew enough to use them safely. By contrast, perceived unfairness was associated with negative attitudes.
Conclusions: Interventions to reduce smart drug use should focus on attitudinal beliefs around potential harm and safety, as well as emphasizing the debate around unfairness.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tine.2019.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stimuli-responsive nanoscale drug delivery system for epilepsy theranostics.
Acta Biomater
January 2025
Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences and School of Basic Medical Sciences, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address:
Epilepsy is a common neurological disease characterized by distinct pathological changes in the epileptogenic zone. Antiseizure drugs (ASDs) are widely used as the primary treatment for epilepsy. To improve the efficiency of ASDs medication, stimuli-responsive nanoscale drug delivery systems (nanoDDSs), triggered by either endogenous or exogenous factors, have been developed and been considered as a noninvasive and spatial-temporal approach to epilepsy theranostics.
View Article and Find Full Text PDFBioactive hydrogel formulations for regeneration of pathological bone defects.
J Control Release
January 2025
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, China. Electronic address:
Bone defects caused by osteoporosis, infection, diabetes, post-tumor resection, and nonunion often cause severe pain and markedly increase morbidity and mortality, which remains a significant challenge for orthopedic surgeons. The precise local treatments to these pathological complications is essential to avoid poor or failed bone repair. Hydrogel formulations serve as injectable innovative platforms that overcome microenvironmental obstacles and as delivery systems for controlled release of various bioactive substances to bone defects in a targeted manner.
View Article and Find Full Text PDFNanoparticles modified with glucose analogs to enhance the permeability of the blood-brain barrier and their accumulation in the epileptic brain.
J Mater Chem B
January 2025
Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, P. R. China.
Drug delivery for epilepsy treatment faces enormous challenges, where the sole focus on enhancing the ability of drugs to penetrate the blood-brain barrier (BBB) through ligand modification is insufficient because of the absence of seizure-specific drug accumulation. In this study, an amphipathic drug carrier with a glucose transporter (GLUT)-targeting capability was synthesised by conjugating 2-deoxy-2-amino-D-glucose (2-DG) to the model carrier DSPE-PEG. A 2-DG-modified nano drug delivery system (NDDS) possessing robust stability and favourable biocompatibility was then fabricated using the nanoprecipitation method.
View Article and Find Full Text PDFThe use of an automatic remote weight management system to track treatment response, identified drugs supply shortage and its consequences: A pilot study.
Digit Health
January 2025
Ohad Cohen Endocrinology, Tel Hashomer, Israel.
Objective: The objective of this pilot study is to evaluate the feasibility of using an automatic weight management system to follow patients' response to weight reduction medications and to identify early deviations from weight trajectories.
Methods: The pilot study involved 11 participants using Semaglutide for weight management, monitored over a 12-month period. A cloud-based, Wi-Fi-enabled remote weight management system collected and analyzed daily weight data from smart scales.
Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.
Sci Rep
January 2025
The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe Road, Zhengzhou, 450052, Henan, China.
Netrin-1 (NTN1) is a laminin-related secreted protein involved in axon guidance and cell migration. Previous research has established a significant connection between NTN1 and nervous system development. In recent years, mounting evidence indicates that NTN1 also plays a crucial role in tumorigenesis and tumor progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!